-

03:43:55 AM

UBX Stock News

UBX - Unity Biotechnology Inc

05/09/23 4:05 PM

Nasdaq : UBX

earningslow float

UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2023. “The recent

RHEA-AI

neutral

04/24/23 7:00 AM

Nasdaq : UBX

clinical triallow float

UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity ( BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks

RHEA-AI

neutral

04/23/23 6:00 PM

Nasdaq : UBX

conferencesclinical triallow float

UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company

RHEA-AI

neutral

03/27/23 7:30 AM

Nasdaq : UBX

clinical triallow float

UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of

RHEA-AI

neutral

03/15/23 4:05 PM

Nasdaq : UBX

earningslow float

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31,

RHEA-AI

neutral

02/28/23 4:05 PM

Nasdaq : UBX

conferenceslow float

UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and

RHEA-AI

neutral

02/15/23 8:00 AM

Nasdaq : UBX

conferenceslow float

UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and

RHEA-AI

neutral

02/09/23 8:00 AM

Nasdaq : UBX

conferenceslow float

UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study

-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET- -Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023- SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023

RHEA-AI

neutral

01/18/23 8:00 AM

Nasdaq : UBX

low float

UNITY Biotechnology Reports Granting of New Employment Inducement Award

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from January 3, 2023, through January 17, 2023, the Compensation

RHEA-AI

neutral

11/08/22 4:10 PM

Nasdaq : UBX

earningslow float

UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates

- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Phase 2 ENVISION Study

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next